These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 35878420)

  • 1. Emerging Nanotechnologies and Microbiome Engineering for the Treatment of Inflammatory Bowel Disease.
    Abed OA; Attlassy Y; Xu J; Han K; Moon JJ
    Mol Pharm; 2022 Dec; 19(12):4393-4410. PubMed ID: 35878420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives.
    Yang C; Merlin D
    Int J Nanomedicine; 2019; 14():8875-8889. PubMed ID: 32009785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticles for oral delivery: targeted therapy for inflammatory bowel disease.
    Li DF; Yang MF; Xu HM; Zhu MZ; Zhang Y; Tian CM; Nie YQ; Wang JY; Liang YJ; Yao J; Wang LS
    J Mater Chem B; 2022 Aug; 10(31):5853-5872. PubMed ID: 35876136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unleashing the Potential of Oral Deliverable Nanomedicine in the Treatment of Inflammatory Bowel Disease.
    Yang C; Sharma K; Mow RJ; Bolay E; Srinivasan A; Merlin D
    Cell Mol Gastroenterol Hepatol; 2024; 18(2):101333. PubMed ID: 38490294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and in vitro characterization of multistage silicon-PLGA budesonide particles for inflammatory bowel disease.
    Leonard F; Srinivasan S; Liu X; Collnot EM; Ferrari M; Lehr CM; Godin B
    Eur J Pharm Biopharm; 2020 Jun; 151():61-72. PubMed ID: 32283213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ROS Scavenging and inflammation-directed polydopamine nanoparticles regulate gut immunity and flora therapy in inflammatory bowel disease.
    Bao M; Wang K; Li J; Li Y; Zhu H; Lu M; Zhang Y; Fan Q; Han L; Wang K; Wang D; Gao Y; Peng B; Ming Z; Liu W
    Acta Biomater; 2023 Apr; 161():250-264. PubMed ID: 36863680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An oral polyphenol host-guest nanoparticle for targeted therapy of inflammatory bowel disease.
    Zhang C; Zeng F; Fan Z; He Z; Tai L; Peng Q; Zhang Y; Chao Z; Jiang W; Jia L; Han L
    Acta Biomater; 2023 Oct; 169():422-433. PubMed ID: 37597682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Size-dependent nanoparticulate drug delivery in inflammatory bowel diseases.
    Youshia J; Lamprecht A
    Expert Opin Drug Deliv; 2016; 13(2):281-94. PubMed ID: 26637060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orally-administered nanomedicine systems targeting colon inflammation for the treatment of inflammatory bowel disease: latest advances.
    Hu S; Zhao R; Xu Y; Gu Z; Zhu B; Hu J
    J Mater Chem B; 2023 Dec; 12(1):13-38. PubMed ID: 38018424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue.
    Hua S; Marks E; Schneider JJ; Keely S
    Nanomedicine; 2015 Jul; 11(5):1117-32. PubMed ID: 25784453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease.
    Xiao B; Merlin D
    Expert Opin Drug Deliv; 2012 Nov; 9(11):1393-407. PubMed ID: 23036075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticles for the regulation of intestinal inflammation: opportunities and challenges.
    Nunes R; Neves JD; Sarmento B
    Nanomedicine (Lond); 2019 Oct; 14(19):2631-2644. PubMed ID: 31612773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulus-responsive drug delivery nanoplatforms for inflammatory bowel disease therapy.
    Long J; Liang X; Ao Z; Tang X; Li C; Yan K; Yu X; Wan Y; Li Y; Li C; Zhou M
    Acta Biomater; 2024 Oct; 188():27-47. PubMed ID: 39265673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microbiome-phage interactions in inflammatory bowel disease.
    Federici S; Kviatcovsky D; Valdés-Mas R; Elinav E
    Clin Microbiol Infect; 2023 Jun; 29(6):682-688. PubMed ID: 36191844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoparticle-mediated gene therapy strategies for mitigating inflammatory bowel disease.
    Verma P; Srivastava A; Srikanth CV; Bajaj A
    Biomater Sci; 2021 Mar; 9(5):1481-1502. PubMed ID: 33404019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.
    Carroll MW; Kuenzig ME; Mack DR; Otley AR; Griffiths AM; Kaplan GG; Bernstein CN; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Benchimol EI
    J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S49-S67. PubMed ID: 31294385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactive oxygen species responsive nanoplatforms as smart drug delivery systems for gastrointestinal tract targeting.
    Bertoni S; Machness A; Tiboni M; Bártolo R; Santos HA
    Biopolymers; 2020 Jan; 111(1):e23336. PubMed ID: 31724750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticle-Based Drug Delivery Systems for Inflammatory Bowel Disease Treatment.
    Gao J; Li J; Luo Z; Wang H; Ma Z
    Drug Des Devel Ther; 2024; 18():2921-2949. PubMed ID: 39055164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advancements in nanoparticle based drug delivery for gastrointestinal disorders.
    Mittal R; Patel AP; Jhaveri VM; Kay SS; Debs LH; Parrish JM; Pan DR; Nguyen D; Mittal J; Jayant RD
    Expert Opin Drug Deliv; 2018 Mar; 15(3):301-318. PubMed ID: 29272976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The future of nanomedicine in optimising the treatment of inflammatory bowel disease.
    Mohan LJ; Daly JS; Ryan BM; Ramtoola Z
    Scand J Gastroenterol; 2019 Jan; 54(1):18-26. PubMed ID: 30678499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.